The Plant-based Vaccines market is defined by the development and production of Vaccines in plant systems. Advantages of Plant-based Vaccines include low-cost and scalable production, ease of oral administration, and potential for heat stability and cold chain independence. Plant production platforms enable rapid development of Vaccines against emerging and pandemic threats.
The Global Plant-based Vaccines Market is estimated to be valued at US$ 113.12 Bn in 2024 and is expected to exhibit a CAGR of 9.6% over the forecast period 2024 to 2031.
Key players operating in the Plant-based Vaccines market are Medicago, Inc., IBIO, Inc., Icon Genetics GmbH, Lumen Bioscience, Inc., British American Tobacco Plc., Creative Biolabs, Inc., Leaf Expression Systems Ltd., ZYUS Life Sciences Inc., PlantForm Corporation, and Infectious Disease Research Institute (IDRI). These leading players are investing in R&D to develop innovative plant-derived Vaccines and pursue partnership opportunities.
The growing demand for efficient, scalable and cost-effective Vaccine production methods is boosting the Plant-based Vaccines market. Plant platforms allow rapid development of Vaccines against emerging diseases and production at a lower cost than egg- or cell-based methods.
Strong support from global health organizations and government research agencies is facilitating the global expansion of the Plant-based Vaccines market. Collaborations between industry and academia also accelerate commercial development and regulatory approval of new plant-made Vaccines.
Market Key Trends
One key trend in the Plant-based Vaccines market is the adoption of transient plant expression systems. Transient expression enables faster development and lower-cost production compared to stable plant transformation. By bypassing the need for plant regeneration, transient systems accelerate vaccine development and allow rapid screening of multiple candidates. This has increased their use for rapid responses to disease outbreaks and pandemic threats.
Threat of new entrants: New entrants face significant costs to develop the new technologies and to upscale production capacity plant-based vaccines.
Bargaining power of buyers: Buyers have moderate bargaining power due to the availability of alternative vaccines.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to the availability of substitute raw materials.
Threat of new substitutes: Substitute options like DNA, RNA, and peptide-based vaccines pose threat to plant-based vaccines.
Competitive rivalry: The market is moderately competitive due to the presence of few established players.
North America dominated the Plant-Based Vaccines Market Size in terms of value in 2024 due to the presence of major vaccine manufacturer in the region. The region is expected to remain the most lucrative market during the forecast period owing to increasing R&D investment for vaccine development.
Asia Pacific is expected to be the fastest growing regional market for plant-based vaccines between 2024 to 2031. This is attributed to rising incidence of infectious diseases, growing population, increasing healthcare expenditure and evolving regulatory landscape in countries like China and India.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it